Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions.
Harshabad SinghYvonne Y LiLiam F SpurrAtul B ShinagareRitika AbhyankarEmma ReillyLauren K BraisAnwesha NagMatthew D DucarAaron R ThornerGeoffrey I ShapiroRachel B KellerCheta SilettiJeffrey W ClarkAnna F FaragoJessica J LinGeorge D DemetriRahul GujrathiMatthew H KulkeLaura E MacConaillAzra H LigonEwa SicinskaMatthew L MeyersonJeffrey A MeyerhardtAndrew D CherniackBrian M WolpinKimmie NgMarios GiannakisJason L HornickJames M ClearyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
RTK fusions in colorectal cancer are a rare, but important disease subgroup that occurs in RAS and BRAF wild-type tumors. Despite enrichment in acquired MMR-D tumors, RTK fusions also occur in MSS colorectal cancer and provide an important therapeutic target.